Why ADHD Pre-Medication Screening Is the Highest-Risk Step in the Private Prescribing Pathway — And What to Do About It

If you prescribe ADHD medication in a private setting, you already know the feeling.

You have a patient in front of you. They've waited months for this appointment. They have a confirmed diagnosis and they want to start medication. And before you can write that prescription, you need to work through a mental checklist that isn't written down anywhere in one place.

Cardiovascular history. Current medications. MAOIs. QT-prolonging drugs. Baseline observations. ECG indications. Contraindications specific to the drug you're about to prescribe.

For lisdexamfetamine alone, there are ten absolute contraindications. For methylphenidate, thirteen — several of which are psychiatric contraindications that don't apply to any other ADHD drug. For atomoxetine, the QT prolongation profile and orthostatic BP considerations add another layer entirely.

Most of us learned this through experience. We've built our own mental frameworks. We cross-reference the BNF, the SPC, the shared care protocol, and our own clinical judgement in real time.

It works. Until it doesn't.

The problem isn't competence. It's consistency.

The risk in private ADHD prescribing isn't that individual prescribers don't know what they're doing. The risk is that without a structured, documented screening process, two prescribers in the same service can reach different conclusions about the same patient — and neither will necessarily be wrong.

One might flag a patient's use of citalopram and request an ECG before initiating. Another might not. One might document a resting heart rate of 102 and note it as a caution. Another might not document it at all.

From a clinical governance perspective, that inconsistency is a liability. From a CQC perspective, it's a gap in your systems and processes. From a medico-legal perspective, it's the kind of thing that becomes relevant when something goes wrong.

What good pre-initiation screening actually looks like

A structured pre-initiation screening for adult ADHD medication should cover five areas:

1. Drug-specific contraindications Not generic contraindications — drug-specific ones. Lisdexamfetamine and methylphenidate share some contraindications but not all. Atomoxetine has a distinct profile. Dexamfetamine has unique contraindications including Tourette syndrome and porphyria that don't apply to the other three.

2. Named drug interactions "Check for interactions" is not a clinical process. Identifying the seven MAOIs by name — phenelzine, tranylcypromine, isocarboxazid, moclobemide, selegiline, rasagiline, safinamide — and confirming washout periods is a clinical process. Identifying all nineteen QT-prolonging drugs your patient might be taking, risk-tiered by severity, is a clinical process.

3. ECG indications Knowing when an ECG is required before initiating is not always straightforward, particularly in patients with cardiac history, family history of sudden cardiac death, or those taking QT-prolonging drugs. This needs to be documented, not assumed.

4. Baseline observations BP, HR, weight, height, BMI — all recorded and flagged against clinical thresholds. A systolic BP of 162 before starting a stimulant is a contraindication. A resting HR of 118 needs to be documented and managed. These aren't catches most prescribers will miss, but they are catches that need to be in the patient record.

5. A structured clinical summary Every screening should end with a documented decision — proceed, review, or do not initiate — with the clinical reasoning recorded. Not in free text. In a reproducible, auditable format.

The documentation gap

Here's the part that doesn't get talked about enough.

Even when prescribers do all of this well, the documentation often doesn't reflect it. A consultation note that says "contraindications discussed, observations taken, patient suitable for lisdexamfetamine 30mg OD" is not a defensible record if something goes wrong.

A record that shows the specific contraindications checked, the medications reviewed for interactions, the baseline observations with values, and a structured decision with clinical reasoning — that is a defensible record.

The screening and the documentation have to happen together. One without the other isn't enough.

What I built — and why

I'm an independent nurse prescriber working across private adult ADHD services. About eighteen months ago I got tired of reinventing this process for every initiation, and I built ADHD Rx Screening.

It's a clinical decision support tool that guides prescribers through a structured pre-initiation screening for all four adult ADHD medications — lisdexamfetamine, methylphenidate, atomoxetine and dexamfetamine. Every section is drug-specific. Every screening generates a structured clinical summary. There's an AI assistant built in for dosing and interaction questions mid-consult.

It's built on NICE NG87 and the national shared care protocols. It's not a tick-box exercise — it's designed to replicate the thinking a thorough, experienced prescriber does naturally, and make it available to every prescriber on every consultation.

Since building it, my pre-initiation consultations are faster, my documentation is stronger, and I'm more confident that I haven't missed anything.

I've made it available to other prescribers because I think the problem I was solving is one most of us share.

If you prescribe ADHD medication privately

Whether you're an independent nurse prescriber, a psychiatrist, or a clinical lead responsible for a prescribing team, the question worth asking is: if your pre-initiation screening process was audited tomorrow, would your documentation show what you actually did?

If the answer is uncertain, it might be worth taking a look.

There's a 14-day free trial at focusgentlyclinical.solutions — no card required. Clinic plans are available for teams of up to 100 prescribers.